Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.
Retinoic acid therapy improves the survival of children with neuroblastoma and 13-cis retinoic acid now forms an important component of treatment for residual disease of stage IV neuroblastoma after chemotherapy. However, although 13-cis retinoic acid induces differentiation, other retinoids are effective at inducing apoptosis of neuroblastoma in vitro, including the novel compounds fenretinide and CD437 and these may be alternative retinoids for neuroblastoma therapy. The aim of our study was to evaluate the ability of fenretinide, CD437 (6-¿3-(1-adamantyl)-4-hydroxyphenyl¿ -2-naphthalene carboxylic acid) and different retinoic acid isomers to induce apoptosis of neuroblastoma in conjunction with the chemotherapeutic drugs, cisplatin, etoposide and carboplatin. Neuroblastoma cell lines were treated with retinoids prior to treatment with chemotherapeutic agents and flow cytometry used to measure apoptosis and free radical generation. Pre-treatment of neuroblastoma cell lines with fenretinide or CD437 prior to treatment with cisplatin, etoposide or carboplatin synergistically increased apoptosis, an effect not seen with 13-cis, all-trans or 9-cis retinoic acid. Contrary to retinoic acid isomers or chemotherapeutic drugs, apoptosis of neuroblastoma cells induced by fenretinide or CD437 was accompanied by the generation of intracellular free radicals. Quenching of fenretinide- or CD437-induced free radicals with antioxidants abolished the synergistic response seen with the subsequent addition of chemotherapeutic agents. Therefore, the generation of free radicals by fenretinide or CD437 may be the key property of these retinoids leading to synergistic responses with chemotherapeutic drugs. Clearly, these synthetic retinoids provide new opportunities for novel neuroblastoma therapy.
Lovat
P E
PE
Department of Child Health, University of Newcastle, Newcastle upon Tyne, United Kingdom.
Ranalli
M
M
Bernassola
F
F
Tilby
M
M
Malcolm
A J
AJ
Pearson
A D
AD
Piacentini
M
M
Melino
G
G
Redfern
C P
CP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D016190:Carboplatin / Q000627:therapeutic use; D002470:Cell Survival; D002945:Cisplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005047:Etoposide / Q000627:therapeutic use; D017313:Fenretinide / Q000008:administration & dosage; D005434:Flow Cytometry; D005609:Free Radicals / Q000032:analysis; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy* / Q000503:physiopathology; D012176:Retinoids / Q000008:administration & dosage; D013997:Time Factors; D014212:Tretinoin / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects
C099555:CD 437; D005609:Free Radicals; D012176:Retinoids; D017313:Fenretinide; D014212:Tretinoin; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin